The global at-home cancer testing market is slated to surge at a CAGR of 5% from 2023 to 2033. According to Future Market Insights, the market is likely to reach US$ 6.9 billion by the end of 2023, and will eventually rise to a valuation of US$ 11.24 billion in 2033. As cancer risks mount, people are increasingly looking for ways to detect possible malignancies prior to the disease’s onset. This fact has led to a proliferation of at-home cancer testing kits.
Cancer is a major public health burden globally. As of 2020, the disease claimed nearly 10 million lives or 1 in 6 deaths. The most common types include breast cancer (2.26 million cases), lung cancer (2.21 million cases), colon & rectum cancer (1.93 million cases), prostate cancer (1.41 million cases), skin (non-melanoma) cancer (1.2 million cases), and stomach cancer (1.09 million cases). Additionally, each year, around 40,000 children develop this deadly disease. Hence, early diagnosis and timely treatment have become necessary.
In the past two years alone, sales of at-home cancer testing kits have risen significantly, thanks to the onset of the novel coronavirus disease pandemic. As healthcare settings reoriented their priorities and resources toward mitigating the infection, on-premise cancer diagnosis and treatment took a back seat. Hence, people began testing and identifying possible signs within their home setting, prompting a flurry of investments in developing easy-to-use testing kits.
The United States is likely to emerge as a promising hub for at-home cancer testing service providers. A major reason attributed to this trend is an absence of in-patient care and therapeutics. A study conducted with regard to cancer treatment reveals that oncology procedures at the Massachusetts General Hospital were 72% of 2019 levels during the last one-half of 2020, and only 84% in 2021. The healthcare system is yet to rebound following a post-pandemic recovery trajectory. Since delays in diagnosis and detection may complicate matters, practitioners are advising patients to opt for home-based testing approaches.
The recent past has seen an increasing prevalence of at-home cancer testing kits, instruments, and reagents. In January 2023, for instance, the renowned stem cell and tissues storage bank provider LifeCell announced the availability of the first at-home self-test kit for screening the presence of the Human Papillomavirus (HPV), the pathogen responsible for causing cervical cancer. This is a revolutionary development, as the disease is most prevalent among women, along with an extremely high mortality rate.
On a similar trajectory, researchers at Purdue University are in the process of developing a paper-based device to detect cervical cancer. Akin to other at-home tests, this testing approach will yield results within a few minutes, doing away with the need to schedule appointments in healthcare settings. Besides convenience, the test is expected to be more affordable and accessible to women, thus preventing the onset of the disease.
Several established market players are concentrating on expanding their oncology research capabilities to develop new and improved testing kits and therapies. In August 2022, Exact Sciences Corp. collaborated with the West German Study Group (WSG), a pioneer in practice-changing clinical studies in breast cancer. The tie-up seeks to further a prospective, multicentre validation study in hormone receptor positive, HER-2 negative early breast cancer patients. This will demonstrate the company’s ability to detect minimal residue disease (MRD) via its tumor-informed ctDNA liquid biopsy test. The combined study, titled ADAPT Triad, is expected to include data from around 3,000 German patients enrolled in two ongoing trials.
| Data Points | Key Statistics |
|---|---|
| Expected Market Value in 2023 | US$ 6.9 billion |
| Anticipated Market Value in 2033 | US$ 11.24 billion |
| Growth Rate (2023 to 2033) | CAGR of 5% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to the latest research by Future Market Insights, At-Home Cancer Testing Market is expected to witness robust growth with 4-5% CAGR during the forecast period from 2021 to 2031. The At-Home Cancer Testing will show growth due to the rising prevalence of cancer globally and an increase in investment to develop at-home cancer testing kits. Therefore, growth at a significantly high CAGR will be expected soon.
The rising geriatric population and cancer prevalence is driving the at-home cancer screening market. Increasing adoption of at-home screening is anticipated to grow the at-home devices for cancer screening. According to the North American Association of Central Cancer in 2020, 1,806,590 new cancer cases and 606,520 cancer deaths are projected to occur in the United States.
Pre-detection of cancer for prevention and early treatment is leading the market in the forecasted period. At-home testing for colon cancer is anticipated to fuel the market in the forecasted period. It is recommended to have a colorectal diagnosis after 50 years of age.
Also, with increasing demand in the field of diagnosis, the major players and different countries made advances in their research and technology for making the process easy, painless, and rapid. All these factors drive the At-Home Cancer Testing Market significantly during the forecast period from 2021 to 2031.
Principal Consultant
USA and Canada will retain the top position in the market of at-home cancer testing due to the rising prevalence of cancer in the region and increasing adoption of home testing kits.
Colorectal cancer is the second most common cause of cancer death in the United States. According to the American Cancer Society in the USA in 2020, 104,610 new cases of colon cancer were detected and 43,340 cases of rectal cancer diagnosed in the USA More than 3000 deaths have been recorded in 2020 due to colorectal cancer.
This rate is higher in patients with age more than 50 years. The high geriatric population will accelerate the at-home cancer testing market. However, some populations need to make aware of the at-home cancer testing availability for early diagnosis. Thus need for home cancer testing is increased significantly.
Europe was hit badly by the corvid-19 pandemic in 2020. This makes them focus primarily on their healthcare sector and developing new technologies and adopting new devices for minimizing the discomfort of the population.
According to European Cancer Information System in 2020, 341,419 new cases were recorded with 156,105 deaths. Deaths have been found higher in aged people. The deaths can only be controlled by early diagnosis and treatment.
Therefore, it is important to adopt such methods as At-Home Cancer Testing and self-testing kits to follow the social distancing and avoid gathering of people at hospitals, clinics, and diagnostic labs. This will result in developing the At-Home Cancer Testing demand in Europe during the forecast period.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Some of the leading manufacturers and suppliers of At-Home Cancer Testing include
These companies followed certain strategies like a partnership, new product launch and approval, mergers and acquisitions to gain a good position in the market. For instance, in August 2018, Exact Sciences and Pfizer announced an agreement through 2021 to co-promote Cologuard.
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides an in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments.
The report also maps the qualitative impact of various market factors on market segments and geographies.
Explore Healthcare Insights
View Reports
At-Home Cancer Testing Market
